Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Biotechnology - Page 73

Biotechnology

Medigen Vaccines announced publication of positive results from preclinical studies of COVID-19 vaccine candidate
Biotechnology | COVID-19 | Therapeutics | Vaccine

Medigen Vaccines announced publication of positive results from preclinical studies of COVID-19 vaccine candidate

On Nov. 19, 2020, Medigen Vaccine Biologics announced that preclinical results of their COVID-19 vaccine candidate had been…

Read More Medigen Vaccines announced publication of positive results from preclinical studies of COVID-19 vaccine candidateContinue

Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot program
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Medical Device

Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot program

On Nov. 19, 2020, Cue Health announced that, as of November 9, the U.S. Department of Health and…

Read More Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot programContinue

Baricitinib received Emergency Use Authorization from FDA for treatment of hospitalized patients with COVID-19
Biotechnology | COVID-19 | FDA | Therapeutics

Baricitinib received Emergency Use Authorization from FDA for treatment of hospitalized patients with COVID-19

On Nov. 19, 2020, Eli Lilly and Incyte announced that the FDA had issued an Emergency Use Authorization…

Read More Baricitinib received Emergency Use Authorization from FDA for treatment of hospitalized patients with COVID-19Continue

XBiotech data showed effective anti-virus activity for antibodies in candidate influenza-COVID-19 therapeutic
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Therapeutics

XBiotech data showed effective anti-virus activity for antibodies in candidate influenza-COVID-19 therapeutic

On Nov. 19, 2020, XBiotech announced data for its breakthrough candidate therapy for treating infections of influenza and…

Read More XBiotech data showed effective anti-virus activity for antibodies in candidate influenza-COVID-19 therapeuticContinue

Texas A&M System, Worlds Inc. collaborated on COVID-19 breathalyzer
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Medical Device

Texas A&M System, Worlds Inc. collaborated on COVID-19 breathalyzer

On Nov. 19, 2020, Dallas-based company, Worlds Inc., the U.S. Air Force and Texas A&M University announced a…

Read More Texas A&M System, Worlds Inc. collaborated on COVID-19 breathalyzerContinue

Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study
Biotechnology | HIV | Therapeutics

Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study

On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…

Read More Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 studyContinue

OHSU study screened wastewater, test volunteers for coronavirus
Biotechnology | Diagnostics | Environmental

OHSU study screened wastewater, test volunteers for coronavirus

On Nov. 18, 2020, Oregon Health & Science University (OHSU) announced an initiative that will attempt to discern…

Read More OHSU study screened wastewater, test volunteers for coronavirusContinue

RedHill’s second COVID-19 candidate cleared by FDA for phase 2/3 Study in symptomatic COVID-19 disease
Biotechnology | COVID-19 | FDA | Therapeutics

RedHill’s second COVID-19 candidate cleared by FDA for phase 2/3 Study in symptomatic COVID-19 disease

On Nov. 17, 2020, RedHill Biopharma announced that the U.S. Food and Drug Administration (FDA) had cleared the…

Read More RedHill’s second COVID-19 candidate cleared by FDA for phase 2/3 Study in symptomatic COVID-19 diseaseContinue

Mayo Clinic reported 900 employees contracted COVID-19 from local community
Biotechnology | COVID-19 | Therapeutics

Mayo Clinic reported 900 employees contracted COVID-19 from local community

On Nov. 17, 2020, the Mayo Clinic reported that more than 900 employees had contracted COVID-19 in the…

Read More Mayo Clinic reported 900 employees contracted COVID-19 from local communityContinue

Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccine
Biotechnology | Infectious Disease | Influenza | NIH | Vaccine

Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccine

On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of…

Read More Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccineContinue

bioMerieux announced CE marking of ARGENE SARS-CoV-2 diagnostic test to include saliva specimens
Biotechnology | COVID-19 | Diagnostics

bioMerieux announced CE marking of ARGENE SARS-CoV-2 diagnostic test to include saliva specimens

On Nov. 16, 2020, bioMerieux announced the expansion of its ARGENE range for the detection of SARS-CoV-2. As…

Read More bioMerieux announced CE marking of ARGENE SARS-CoV-2 diagnostic test to include saliva specimensContinue

RedHill completed enrollment for COVID-19 US phase 2 study with opaganib
Biotechnology | COVID-19 | Therapeutics

RedHill completed enrollment for COVID-19 US phase 2 study with opaganib

On Nov. 16, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…

Read More RedHill completed enrollment for COVID-19 US phase 2 study with opaganibContinue

Wellcome Sanger Institute and COG-UK received £122M UK investment for COVID-19 genomic surveillance
Biotechnology | COVID-19 | Diagnostics | Genomics | Infectious Disease | Therapeutics | Vaccine

Wellcome Sanger Institute and COG-UK received £122M UK investment for COVID-19 genomic surveillance

On Nov. 16, 2020, the UK Department for Health and Social Care Testing Innovation Fund announced £12.2M funding…

Read More Wellcome Sanger Institute and COG-UK received £122M UK investment for COVID-19 genomic surveillanceContinue

Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures

On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…

Read More Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperaturesContinue

Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidate
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Vaccine

Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidate

On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…

Read More Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidateContinue

INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800

On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…

Read More INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800Continue

Aegis Sciences launched combined test for SARS-CoV-2 and influenza A/B virus
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Aegis Sciences launched combined test for SARS-CoV-2 and influenza A/B virus

On Nov. 16, 2020, Aegis Sciences announced that it had launched a combined test for SARS-CoV-2 and influenza…

Read More Aegis Sciences launched combined test for SARS-CoV-2 and influenza A/B virusContinue

European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Vaccine

European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19

On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…

Read More European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19Continue

Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
Biotechnology | COVID-19 | Infectious Disease | Life Science History | NIH | Vaccine

Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study

On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…

Read More Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE studyContinue

CHMP recommended EU approval of Roche’s Xofluza (baloxavir marboxil) for the treatment of influenza
Biotechnology | Infectious Disease | Influenza | Therapeutics

CHMP recommended EU approval of Roche’s Xofluza (baloxavir marboxil) for the treatment of influenza

On Nov. 13, 2020, Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read More CHMP recommended EU approval of Roche’s Xofluza (baloxavir marboxil) for the treatment of influenzaContinue

FDA approved Merck’s KEYTRUDA (pembrolizumab) in combination with chemo for patients with TNBC
Biotechnology | Chemical | FDA | Therapeutics

FDA approved Merck’s KEYTRUDA (pembrolizumab) in combination with chemo for patients with TNBC

On Nov. 13, 2020, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck’s…

Read More FDA approved Merck’s KEYTRUDA (pembrolizumab) in combination with chemo for patients with TNBCContinue

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
Biotechnology | COVID-19 | FDA | Therapeutics

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

On Nov. 13, 2020, NeuroRx and Relief Therapeutics announced that to-date, 150 patients (out of a targeted enrollment…

Read More NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory FailureContinue

Agilent received expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancer
Biotechnology | FDA | Oncology | Therapeutics

Agilent received expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancer

On Nov. 13, 2020, Agilent Technologies announced it had received U.S. Food and Drug Administration (FDA) approval for…

Read More Agilent received expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancerContinue

Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19

On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…

Read More Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19Continue

Respiratory failure in COVID-19 usually not driven by cytokine storm
Biotechnology | COVID-19 | Diagnostics | Non-Profit Research

Respiratory failure in COVID-19 usually not driven by cytokine storm

On Nov. 13, 2020, a study from Washington University School of Medicine in St. Louis and St. Jude…

Read More Respiratory failure in COVID-19 usually not driven by cytokine stormContinue

CALAVI did not meet the primary endpoint in patients hospitalised with respiratory symptoms of COVID-19
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

CALAVI did not meet the primary endpoint in patients hospitalised with respiratory symptoms of COVID-19

On Nov. 12, 2020, AstraZeneca announced that the CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised…

Read More CALAVI did not meet the primary endpoint in patients hospitalised with respiratory symptoms of COVID-19Continue

CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics
Biotechnology | COVID-19 | Vaccine

CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics

On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…

Read More CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logisticsContinue

Wren Laboratories launched saliva-based PCR COVID-19 test
Biotechnology | COVID-19 | Diagnostics | FDA

Wren Laboratories launched saliva-based PCR COVID-19 test

On Nov. 12, 2020, Wren Laboratories announced that it had been granted an emergency use authorization by the…

Read More Wren Laboratories launched saliva-based PCR COVID-19 testContinue

Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2
Biotechnology | COVID-19 | Therapeutics | Vaccine

Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2

On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…

Read More Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2Continue

DSMB analysis recommended continuance of P3 COVID-19 ARDS trial
Biotechnology | COVID-19 | Therapeutics

DSMB analysis recommended continuance of P3 COVID-19 ARDS trial

On Nov. 11, 2020, Mesoblast announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with…

Read More DSMB analysis recommended continuance of P3 COVID-19 ARDS trialContinue

Page navigation

Previous PagePrevious 1 … 71 72 73 74 75 … 169 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiovascular
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search